Despite improvements in neuroblastoma treatment, survival figures lag behind those of many other childhood malignancies. New ...

About Y-mAbs Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, radioimmunotherapy and antibody-based therapeutic cancer products. The ...

Journal of Nuclear Medicine January 2025, jnumed.124.268695; DOI: https://doi.org/10.2967/jnumed.124.268695 ...

Y-mAbs Therapeutics has undergone a significant transformation, restructuring its operations to concentrate on radioimmunotherapy. This strategic shift has placed the company at the forefront of ...